Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028846 · ClinicalTrials.gov registry record · Phase 4
Central Mechanisms That Regulate Glucose Metabolism in Humans
A Phase 4 study, sponsored by Meredith Hawkins.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT01028846 is a Phase 4 study that was terminated before completion, run by Meredith Hawkins. The registered enrollment target is 10 participants.
The verdict
NCT01028846, a Phase 4 study, was terminated before completion, sponsored by Meredith Hawkins.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
Type 2 diabetes is a chronic condition that affects the ability of the body to regulate glucose (sugar). When glucose levels are low, the liver can make glucose to increase levels in the body. This important process is called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to coordinate this process by communicating with the liver through potassium channels. Control of EGP can be impaired in people with type 2 diabetes, which may contribute to the high levels of glucose seen in these individuals. The purpose of this study is to understand how activating these potassium channels in the control centers of the brain with a medication called diazoxide might inhibit the amount of glucose made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn causes hyperglycemia (high levels of sugar in the blood) that leads to diabetes complications.
Interventions
- DRUG Placebo
- DRUG Diazoxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-11-02 |
| Est. Completion | 2007-12-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028846
The ClinicalTrials.gov registry entry for NCT01028846 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meredith Hawkins, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01028846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01028846 about?
NCT01028846 is a clinical study titled "Central Mechanisms That Regulate Glucose Metabolism in Humans". Type 2 diabetes is a chronic condition that affects the ability of the body to regulate glucose (sugar). When glucose levels are low, the liver can make glucose to increase levels in the body. This important process is called endogenous glucose production (EGP). Previous studies suggest that the cen...
What is the current status of trial NCT01028846?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2006-11-02. Estimated completion is 2007-12-05.
What interventions are being tested in trial NCT01028846?
The interventions under investigation include: Placebo (DRUG), Diazoxide (DRUG).
Who is sponsoring clinical trial NCT01028846?
This trial is sponsored by Meredith Hawkins, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.